Evidence map›Paper›PMID 32612358›Full record

ArticleInternational journal of nanomedicine2020

Artemisinin Loaded mPEG-PCL Nanoparticle Based Photosensitive Gelatin Methacrylate Hydrogels for the Treatment of Gentamicin Induced Hearing Loss.

Xiaohua Li, Yanchun Wang, Feilong Xu, Feng Zhang, Ying Xu, Lei Tang, Thomas J Webster

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Xiaohua LiDepartment of Otolaryngology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Yanchun WangDepartment of Chinese Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, People's Republic of China.
Feilong XuDepartment of Otolaryngology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Feng ZhangDepartment of Otolaryngology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Ying XuCollege of Pharmacy, Jiangsu University, Zhenjiang 212013, People's Republic of China.
Lei TangCollege of Pharmacy, Jiangsu University, Zhenjiang 212013, People's Republic of China.
Thomas J WebsterDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0002-2028-5969
First Affiliated Hospital of Zhengzhou University · CNJiangsu University · CNHenan University · CNNortheastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveArtemisinin (ART) is a natural anti-malarial sesquiterpene lactone which has the ability to treat and activate the CLRN1 pathway to play a pivotal role in hearing loss and hair cell function. To investigate the therapeutic effect of ART in hearing loss induced by gentamicin (GM), an ART-loaded poly(ethylene glycol)-b-poly(ε-caprolactone) mPEG-PCL nanoparticle-based photosensitive hydrogel was developed and tested in this study. MATERIALS AND

methodsArtemisinin-loaded mPEG-PCL nanoparticles (mPEG-PCL-ART-NPs) were prepared by a double emulsion method and the formulation was optimized by an orthogonal experimental design. The particle size, zeta potential, morphology and in vitro dissolution of the mPEG-PCL-ART-NPs were well characterized. Biocompatibility of the mPEG-PCL-ART-NPs were tested on HeLa cells with an MTT assay. The photo-crosslinkable biodegradable gelatin methacrylate (GelMA) hydrogel was prepared and its physicochemical properties (such as substitution, photocrosslinking efficiency, cell viability morphology, mechanical and swelling properties) were evaluated. Finally, mPEG-PCL-ART-FITC-NPs, loaded mPEG-PCL-ART-NPs, and loaded mPEG-PCL-ART-NPs-GelMA hydrogels were fabricated and a GM toxicity-induced guinea pig ear damage model was established to determine the effectiveness of the materials on returning auditory function and cochlea pathomorphology.

resultsThe zeta potential of the mPEG-PCL-ART-NPs was about -38.64 ± 0.21 mV and the average size was 167.51 ± 1.87 nm with an encapsulation efficacy of 81.7 ± 1.46%. In vitro release studies showed that the mPEG-PCL-ART-NPs possessed a sustained-release effect and the MTT experiments showed good biocompatibility properties of the drug-loaded nanoparticles. The results indicated that the 5% GelMA with MA-4% hydrogel had a better crosslinking density and 3D structure for drug loading and drug delivery than controls. Skin penetration results showed that the mPEG-PCL-ART-NPs increased adhesive capacity and avoided fast diffusion in the skin. Most importantly, auditory brainstem response results indicated that the mPEG-PCL-ART-NPs-GelMA hydrogel alleviated hearing loss induced by GM.

conclusionThese results suggested that the presently fabricated mPEG-PCL-ART-NPs-GelMA hydrogels are promising formulations for the treatment of hearing loss induced by GM and lay the foundation for further clinical research of inner ear induction therapy.

Indexed as

AnimalsArtemisininsDrug Delivery SystemsEthylene GlycolsGelatinGentamicinsGuinea PigsHearing LossHeLa CellsHumansHydrogelsMethacrylatesNanoparticlesParticle SizePolyestersPolyethylene GlycolsartemisininArtemisininsEthylene GlycolsGelatinGentamicinsHydrogelsMethacrylatesmethoxy poly(ethylene glycol-co-epsilon-caprolactone)poly(epsilon-caprolactone)-b-poly(ethylene glycol)PolyestersPolyethylene GlycolsartemisininGelMA hydrogelgentamicinhearing lossmPEG-PCL nanoparticles

Identifiers

PMID32612358
PMCPMC7323796
OpenAlexW3037771268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.